Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

ATPase Domain AFG3L2 Mutations Alter OPA1 Processing and Cause Optic Neuropathy.

Tytuł:
ATPase Domain AFG3L2 Mutations Alter OPA1 Processing and Cause Optic Neuropathy.
Autorzy:
Caporali L; IRCCS Istituto delle Scienze Neurologiche di Bologna, UOC Clinica Neurologica, Bologna, Italy.
Magri S; Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Legati A; Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Del Dotto V; Neurology Unit, Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
Tagliavini F; IRCCS Istituto delle Scienze Neurologiche di Bologna, UOC Clinica Neurologica, Bologna, Italy.
Balistreri F; Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Nasca A; Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
La Morgia C; IRCCS Istituto delle Scienze Neurologiche di Bologna, UOC Clinica Neurologica, Bologna, Italy.; Neurology Unit, Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
Carbonelli M; IRCCS Istituto delle Scienze Neurologiche di Bologna, UOC Clinica Neurologica, Bologna, Italy.
Valentino ML; IRCCS Istituto delle Scienze Neurologiche di Bologna, UOC Clinica Neurologica, Bologna, Italy.; Neurology Unit, Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
Lamantea E; Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Baratta S; Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Schöls L; Department of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany.; German Center for Neurodegenerative Diseases, Tübingen, Germany.
Schüle R; Department of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany.; German Center for Neurodegenerative Diseases, Tübingen, Germany.
Barboni P; Studio Oculistico D'Azeglio, Bologna, Italy.; IRCCS Ospedale San Raffaele, Milan, Italy.
Cascavilla ML; IRCCS Ospedale San Raffaele, Milan, Italy.
Maresca A; IRCCS Istituto delle Scienze Neurologiche di Bologna, UOC Clinica Neurologica, Bologna, Italy.
Capristo M; IRCCS Istituto delle Scienze Neurologiche di Bologna, UOC Clinica Neurologica, Bologna, Italy.
Ardissone A; Unit of Child Neurology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Pareyson D; Unit of Rare Neurodegenerative and Neurometabolic Diseases, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Cammarata G; Neuro-Ophthalmology Center and Ocular Electrophysiology Laboratory, IRCCS Istituto Auxologico Italiano, Capitanio Hospital, Milan, Italy.
Melzi L; Neuro-Ophthalmology Center and Ocular Electrophysiology Laboratory, IRCCS Istituto Auxologico Italiano, Capitanio Hospital, Milan, Italy.
Zeviani M; Department of Neuroscience, University of Padua, Padua, Italy.
Peverelli L; Neurology Unit, Azienda Socio Sanitaria Territoriale Lodi, Ospedale Maggiore di Lodi, Lodi, Italy.
Lamperti C; Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Marzoli SB; Neuro-Ophthalmology Center and Ocular Electrophysiology Laboratory, IRCCS Istituto Auxologico Italiano, Capitanio Hospital, Milan, Italy.
Fang M; Beijing Genomics Institute-Shenzhen, Shenzhen, China.
Synofzik M; Department of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany.; German Center for Neurodegenerative Diseases, Tübingen, Germany.
Ghezzi D; Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.; Department of Medical-Surgical Physiopathology and Transplantation, University of Milan, Milan, Italy.
Carelli V; IRCCS Istituto delle Scienze Neurologiche di Bologna, UOC Clinica Neurologica, Bologna, Italy.; Neurology Unit, Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
Taroni F; Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Źródło:
Annals of neurology [Ann Neurol] 2020 Jul; Vol. 88 (1), pp. 18-32. Date of Electronic Publication: 2020 Apr 21.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Publication: New York, NY : Wiley-Liss
Original Publication: Boston, Little, Brown.
MeSH Terms:
ATP-Dependent Proteases/*genetics
ATPases Associated with Diverse Cellular Activities/*genetics
GTP Phosphohydrolases/*genetics
Optic Atrophy/*genetics
Optic Nerve Diseases/*genetics
Adolescent ; Adult ; Aged ; Child ; Female ; Genetic Testing ; High-Throughput Nucleotide Sequencing ; Humans ; Male ; Middle Aged ; Mutation ; Pedigree ; Exome Sequencing ; Young Adult
References:
Biomed Rep. 2017 Nov;7(5):451-454. (PMID: 29181157)
Nat Rev Neurol. 2015 Jan;11(1):11-24. (PMID: 25486875)
Acta Neuropathol. 2016 Dec;132(6):789-806. (PMID: 27696015)
Neurobiol Dis. 2019 Apr;124:14-28. (PMID: 30389403)
Prog Retin Eye Res. 2011 Mar;30(2):81-114. (PMID: 21112411)
Nat Genet. 2000 Oct;26(2):207-10. (PMID: 11017079)
Brain. 2010 Mar;133(Pt 3):771-86. (PMID: 20157015)
Brain. 2015 Jan;138(Pt 1):e321. (PMID: 25146916)
Orphanet J Rare Dis. 2012 Jul 09;7:46. (PMID: 22776096)
Front Genet. 2014 Nov 20;5:412. (PMID: 25477904)
Brain. 2012 Oct;135(Pt 10):2980-93. (PMID: 23065789)
J Med Genet. 2013 Dec;50(12):848-58. (PMID: 24136862)
Ophthalmology. 2013 Aug;120(8):1712-1712.e1. (PMID: 23916084)
Hum Mutat. 2018 Dec;39(12):2060-2071. (PMID: 30252181)
Crit Rev Biochem Mol Biol. 2007 May-Jun;42(3):221-42. (PMID: 17562452)
Mol Cell. 2019 Sep 5;75(5):1073-1085.e6. (PMID: 31327635)
J Cell Biol. 2007 Aug 27;178(5):749-55. (PMID: 17709429)
Biochim Biophys Acta Mol Basis Dis. 2018 Oct;1864(10):3496-3514. (PMID: 30293569)
Brain. 2008 Feb;131(Pt 2):338-51. (PMID: 18158317)
EMBO J. 2007 Jan 24;26(2):325-35. (PMID: 17245427)
Hum Mutat. 2015 Jan;36(1):20-5. (PMID: 25243597)
EMBO J. 2011 May 24;30(13):2545-56. (PMID: 21610694)
PLoS Genet. 2011 Oct;7(10):e1002325. (PMID: 22022284)
J Med Genet. 2004 Sep;41(9):e110. (PMID: 15342707)
Nat Genet. 2000 Oct;26(2):211-5. (PMID: 11017080)
J Clin Invest. 2004 Jan;113(2):231-42. (PMID: 14722615)
Brain. 2017 Oct 1;140(10):2586-2596. (PMID: 28969390)
Am J Med Genet A. 2011 Jun;155A(6):1298-313. (PMID: 21538838)
Cell Metab. 2014 Apr 1;19(4):630-41. (PMID: 24703695)
Mol Biol Cell. 2009 Oct;20(19):4216-24. (PMID: 19656850)
Elife. 2016 Aug 06;5:. (PMID: 27495975)
Cell Res. 2018 Mar;28(3):296-306. (PMID: 29451229)
Ann Neurol. 2015 Jul;78(1):21-38. (PMID: 25820230)
Arch Neurol. 2011 Jan;68(1):67-73. (PMID: 20837821)
Front Genet. 2015 Oct 19;6:311. (PMID: 26539208)
Nat Genet. 2010 Apr;42(4):313-21. (PMID: 20208537)
Brain. 2014 May;137(Pt 5):1323-36. (PMID: 24727571)
Cell. 2005 Oct 21;123(2):277-89. (PMID: 16239145)
Prog Retin Eye Res. 2004 Jan;23(1):53-89. (PMID: 14766317)
J Clin Invest. 2012 Nov;122(11):4048-58. (PMID: 23041622)
J Mol Biol. 2002 Nov 8;323(5):835-43. (PMID: 12417197)
Brain. 2008 Feb;131(Pt 2):352-67. (PMID: 18222991)
Front Genet. 2018 Dec 07;9:625. (PMID: 30581454)
J Cell Biol. 2015 Oct 26;211(2):373-89. (PMID: 26504172)
Brain. 2014 Aug;137(Pt 8):2164-77. (PMID: 24970096)
Orphanet J Rare Dis. 2017 May 12;12(1):89. (PMID: 28494813)
J Cell Sci. 2016 Jun 15;129(12):2297-306. (PMID: 27189080)
J Cell Biol. 2014 Mar 17;204(6):919-29. (PMID: 24616225)
Hum Mol Genet. 2012 Sep 1;21(17):3858-70. (PMID: 22678058)
Cell. 2013 Sep 26;155(1):160-71. (PMID: 24055366)
Grant Information:
MC_EX_MR/P007031/1 United Kingdom MRC_ Medical Research Council; MC_UP_1002/1 United Kingdom MRC_ Medical Research Council; MC_UU_00015/5 United Kingdom MRC_ Medical Research Council; MRF_MRF-155-0001-S-MARTI United Kingdom MRF MRF; MRF_MRF-155-0005-RG-ZEVI-C0784 United Kingdom MRF MRF; MRF_MRF-155-0002-RG-ZEVIA United Kingdom MRF MRF
Substance Nomenclature:
EC 3.4.21.- (ATP-Dependent Proteases)
EC 3.4.24.- (AFG3L2 protein, human)
EC 3.6.1.- (GTP Phosphohydrolases)
EC 3.6.1.- (OPA1 protein, human)
EC 3.6.4.- (ATPases Associated with Diverse Cellular Activities)
Entry Date(s):
Date Created: 20200329 Date Completed: 20201013 Latest Revision: 20221207
Update Code:
20240105
PubMed Central ID:
PMC7383914
DOI:
10.1002/ana.25723
PMID:
32219868
Czasopismo naukowe
Objective: Dominant optic atrophy (DOA) is the most common inherited optic neuropathy, with a prevalence of 1:12,000 to 1:25,000. OPA1 mutations are found in 70% of DOA patients, with a significant number remaining undiagnosed.
Methods: We screened 286 index cases presenting optic atrophy, negative for OPA1 mutations, by targeted next generation sequencing or whole exome sequencing. Pathogenicity and molecular mechanisms of the identified variants were studied in yeast and patient-derived fibroblasts.
Results: Twelve cases (4%) were found to carry novel variants in AFG3L2, a gene that has been associated with autosomal dominant spinocerebellar ataxia 28 (SCA28). Half of cases were familial with a dominant inheritance, whereas the others were sporadic, including de novo mutations. Biallelic mutations were found in 3 probands with severe syndromic optic neuropathy, acting as recessive or phenotype-modifier variants. All the DOA-associated AFG3L2 mutations were clustered in the ATPase domain, whereas SCA28-associated mutations mostly affect the proteolytic domain. The pathogenic role of DOA-associated AFG3L2 mutations was confirmed in yeast, unraveling a mechanism distinct from that of SCA28-associated AFG3L2 mutations. Patients' fibroblasts showed abnormal OPA1 processing, with accumulation of the fission-inducing short forms leading to mitochondrial network fragmentation, not observed in SCA28 patients' cells.
Interpretation: This study demonstrates that mutations in AFG3L2 are a relevant cause of optic neuropathy, broadening the spectrum of clinical manifestations and genetic mechanisms associated with AFG3L2 mutations, and underscores the pivotal role of OPA1 and its processing in the pathogenesis of DOA. ANN NEUROL 2020 ANN NEUROL 2020;88:18-32.
(© 2020 The Authors. Annals of Neurology published by Wiley Periodicals, Inc. on behalf of American Neurological Association.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies